Ionis reports a positive PhIII for volanesorsen in rare metabolic disorders
Investigators for Ionis Pharmaceuticals $IONS say they gathered positive evidence of efficacy for their late-stage drug volanesorsen in rare cases of metabolic diseases.
The drug produced a mean reduction of 71.2% in triglycerides among the 113 patients in the study who took the treatment over 13 weeks. That compares to a negligible reduction among the placebo arm of the study.
In addition, 82% of patients treated with volanesorsen achieved triglyceride levels less than 500 mg/dl after 13 weeks of treatment, compared to 14% of placebo-treated patients (p<0.0001).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
